Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024

Beam Therapeutics Inc.

Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.
Annual base salary of $575,000; sign-on bonus of $325,000; target annual incentive bonus of 50% of salary.
Granted incentive stock option for 160,000 shares and restricted stock units for 80,000 shares, both vesting over four years.
Under the offer letter, severance includes 12 months base salary and COBRA premiums if terminated without cause.
Appointment effective December 19, 2024; Emany will serve as principal financial officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.